Mitsubishi Tanabe Pharma and AstraZeneca have formed a three-year research collaboration in the area of diabetic nephropathy. The aim of the collaboration is to validate and progress research targets and molecules into clinical development.

The collaboration will span from target selection up to the delivery of small-molecule candidate drugs. Targets from the companies’ early-research portfolio have been identified, and additional targets may be included under the collaboration at a later stage, if mutually desired. The research will be performed in parallet at Mitsubishi Tanabe  Pharma’s facilities in Japan and AstraZeneca’s Cardiovascular and Metabolic Disease Innovative Medicines Unit in Mölndal, Sweden.

Source: Mitsubishi Tanabe Pharma